Clinical Trials · NCT06345079
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Enrollment
- 78
- Start date
- Oct 2024
- Locations
- 12 sites, Australia, Canada
- Primary endpoint
- 20-month progression free survival rate after PRRT